Join Daniel Swanson as he presents Building Flexibility for Multiple Cell Therapy Processes at the ISPE 2020 Biopharmaceutical Manufacturing Virtual Conference.

Many cell therapy firms have a diverse pipeline of promising drug candidates and are faced with the growing challenge of how to manufacture these drugs in a safe, timely, and cost-effective manner. Failed clinical trials leave abandoned assets behind, but manufacturing multiple products in the same facility can mitigate much of the associated risk costs.  To manufacture multiple cell therapy products safely, a deliberate strategy needs to be implemented from the inception of facility design. This topic addresses the cell therapy challenge of building a commercial facility for products that are still in clinical trials and will assess the best practices and case studies of building flexibility of multiple products in the same facility and weigh the benefits and cost of the flexibility.

Read more and register here: https://ispe.org/conferences/2020-ispe-biopharmaceutical-manufacturing-virtual-conference